Literature DB >> 10527295

Lifetime health and economic consequences of obesity.

D Thompson1, J Edelsberg, G A Colditz, A P Bird, G Oster.   

Abstract

BACKGROUND: Obesity is an established risk factor for several chronic diseases. The lifetime health and economic consequences of obesity for individual patients have not been documented.
OBJECTIVE: To estimate the lifetime health and economic consequences of obesity.
METHODS: We developed a dynamic model of the relationship between body mass index and the risks and associated costs of 5 obesity-related diseases: hypertension, hypercholesterolemia, type 2 diabetes mellitus, coronary heart disease, and stroke. The model was estimated using data from the Third National Health and Nutrition Examination Survey, the Framingham Heart Study, and other secondary sources. We used this model to estimate (1) risks of hypertension, hypercholesterolemia, and type 2 diabetes mellitus at future ages; (2) lifetime risks of coronary heart disease and stroke; (3) life expectancy; and (4) expected lifetime medical care costs of these 5 diseases for men and women aged 35 to 64 years with body mass indexes of 22.5, 27.5, 32.5, and 37.5 kg/m2 (nonobese and mildly, moderately, and severely obese, respectively).
RESULTS: Disease risks and costs increase substantially with increased body mass index. The risk of hypertension for moderately obese 45- to 54-year-old men, for example, is roughly 2-fold higher than for their nonobese peers (38.1% vs 17.7%), whereas the risk of type 2 diabetes mellitus is almost 3-fold higher (8.1% vs 3.0%). Lifetime risks of coronary heart disease and stroke are similarly elevated (41.8% vs 34.9% and 16.2% vs 13.9%, respectively), whereas life expectancy is reduced by 1 year (26.5 vs 27.5 years). Total discounted lifetime medical care costs for the treatment of these 5 diseases are estimated to differ by $10,000 ($29,600 vs $19,600). Similar results were obtained for women.
CONCLUSIONS: The lifetime health and economic consequences of obesity are substantial and suggest that efforts to prevent or reduce this problem might yield significant benefits.

Entities:  

Mesh:

Year:  1999        PMID: 10527295     DOI: 10.1001/archinte.159.18.2177

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  102 in total

Review 1.  The increasing necessity for market-based pharmaceutical prices.

Authors:  J E Calfee
Journal:  Pharmacoeconomics       Date:  2000       Impact factor: 4.981

2.  Drugs are not best for obesity.

Authors:  E M Berry
Journal:  BMJ       Date:  2001-09-08

3.  Implantable gastric stimulation (IGS) as therapy for human morbid obesity: report from the 2001 IFSO symposium in Crete.

Authors:  Robert J Greenstein; Mitiku Belachew
Journal:  Obes Surg       Date:  2002-04       Impact factor: 4.129

Review 4.  Socioeconomic issues affecting the treatment of obesity in the new millennium.

Authors:  L F Martin; A Robinson; B J Moore
Journal:  Pharmacoeconomics       Date:  2000-10       Impact factor: 4.981

5.  A cost-benefit analysis of bariatric surgery on the South Plains region of Texas.

Authors:  Bradley T Ewing; Mark A Thompson; Mitchell S Wachtel; Eldo E Frezza
Journal:  Obes Surg       Date:  2011-05       Impact factor: 4.129

6.  The association between obesity and urban food environments.

Authors:  J Nicholas Bodor; Janet C Rice; Thomas A Farley; Chris M Swalm; Donald Rose
Journal:  J Urban Health       Date:  2010-09       Impact factor: 3.671

7.  Mechanisms by which childhood personality traits influence adult health status: educational attainment and healthy behaviors.

Authors:  Sarah E Hampson; Lewis R Goldberg; Thomas M Vogt; Joan P Dubanoski
Journal:  Health Psychol       Date:  2007-01       Impact factor: 4.267

8.  Long-term obesity and avoidable hospitalization among younger, middle-aged, and older adults.

Authors:  Markus H Schafer; Kenneth F Ferraro
Journal:  Arch Intern Med       Date:  2007-11-12

9.  Use of complementary and alternative therapies by overweight and obese adults.

Authors:  Suzanne M Bertisch; Christina C Wee; Ellen P McCarthy
Journal:  Obesity (Silver Spring)       Date:  2008-05-01       Impact factor: 5.002

10.  Healthcare costs and obesity prevention: drug costs and other sector-specific consequences.

Authors:  David R Rappange; Werner B F Brouwer; Rudolf T Hoogenveen; Pieter H M Van Baal
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.